NCT03168607Unknown2 期
Phase II Study of FOLFIRI as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma
Peking University1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2017年5月2日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
Currently, there is no standard second line treatment for patients with neuroendocrine carcinoma. Irinotecan monotherapy or combination regimen has shown promising in previous study. The study was designed to confirm thet FOLFIRI regimen can be used as a second-line regimen for patients with advanced or metastatic neuroendocrine carcinoma who have progressed after first-line chemotherapy with platinum based regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •sign written informed consent form
- •age ≥ 18 years
- •pathologically confirmed poorly-differentiated neuroendocrine carcinoma, G3(Ki67>20%);
- •No prior antitumor treatment with irinotecan, progress after first line chemotherapy with platinum-based regimen. For recurrent patients after radical surgery, platinum-based adjuvant chemotherapy should beyond 6 months prior to randomization;
- •At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions);
- •Screening laboratory values must meet the following criteria (within past 7 days): hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN;
- •Predicted survival >=3 months;
- •Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;
- •Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
排除标准
- •Hypersensitivity to IRI,5-HT3 receptor antagonists;
- •Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- •Received surgery within past 4 weeks, or have not recovered from surgery;
- •Severe diarrhea;
- •Concurrent severe infection；
- •Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including severe liver disease (active hepatitis, cirrhosis), uncontrolled diabetes or hypertension, or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
- •Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment)；
- •Meningeal carcinomatosis;
- •Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease；
- •Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency；
- •Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;
- •History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible；
- •Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；
- •Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
研究组 & 干预措施
FOLFIRI
Experimental
Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
干预措施: FOLFIRI Protocol (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation by RECIST 1.1
次要结局
- Incidence of Treatment-related Adverse Events （Safety and Tolerability）(From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)
- Progression-free survival(baseline, every 8 weeks up to 1 year after last patient first treatment)
- Overall survival(baseline, every 8 weeks up to 1 year after last patient first treatment)
研究者
Shen Lin
MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital
Peking University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine CarcinomaNeuroendocrine CarcinomaNCT03279614Peking University45
已完成
2 期
FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal CarcinomaAdvanced Esophageal CarcinomaNCT02023593Yuhong Li35
进行中（未招募）
不适用
Folfiri as Second-Line chemotherapy for Advanced Pancreatic cancer:a GISCAD Phase II study - SLAP (Second Line Advanced Pancreas)Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must have been received a first-line chemotherapy (one line only) with Gemcitabin +/Platinoid(Cisplatin,Oxaliplatin,Carboplatin)MedDRA version: 14.1Level: LLTClassification code 10013250Term: Disorder pancreasSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2008-004637-16-ITGISCAD
Unknown
2 期
mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the EsophagusAdvanced Esophageal CarcinomaNCT01486992Peking University40
Unknown
2 期
mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical TrialAdvanced Esophageal CarcinomaNCT01044420Peking University50